Oral precursors / What studies used
NAD oral dosage depends on the ingredient
Before looking at an amount, check the name beside it. Much of the human oral research involves NR or NMN, ingredients used to make NAD+, rather than NAD+ itself. The numbers here describe studies. They aren’t a personal schedule.
NMN and muscle response to insulin
Researchers in Yoshino and colleagues’ trial gave prediabetic, postmenopausal women oral nicotinamide mononucleotide (NMN) at 250 mg daily for ten weeks. They found improved muscle insulin sensitivity, meaning muscle responded better to insulin under the study’s testing conditions.
Body composition and HbA1c, a longer-term blood-sugar marker, didn’t change. So the useful finding is narrower than “better metabolic health.” It doesn’t establish an amount for people with different health histories or for another ingredient.
NR and a blood measurement
Researchers in Conze and colleagues’ trial gave healthy overweight adults oral nicotinamide riboside (NR) at 100, 300 or 1,000 mg daily for eight weeks. They found larger rises in whole-blood NAD+ at higher amounts. They reported no significant difference in adverse events from placebo.
The blood result doesn’t identify the amount that gives the best health outcome. Eight weeks also can’t settle safety over years. And NR amounts don’t double as NMN amounts: they’re different ingredients, even though both help the body make NAD+.
The infusion study is a different comparison
In the six-hour NAD+ infusion pilot, researchers gave healthy men intravenous NAD+ at 3 µmol/min over six hours. That unit describes the amount of substance delivered per minute. The study followed NAD+ and related substances in blood and urine.
This wasn’t an oral trial or a study establishing a treatment amount for heart disease. Setting its numbers beside oral trial amounts doesn’t create a conversion chart. The IV discussion explains what the pilot can tell us.
What would a prescriber need to know?
A review of human precursor studies found limited evidence of health benefits. A number from one trial can’t stand in for an assessment of your health, medicines and reason for considering treatment. A prescriber decides whether prescribing is appropriate.
Useful questions start small: Which ingredient and route? What benefit is being considered? Did a study measure that benefit in people with a similar health history?
For a compounded preparation, quality matters alongside amount. Compounded medicines are not FDA-approved, and a study amount says nothing about the quality of a particular preparation. Research gives us something to discuss, rather than a ready-made plan.
Keep reading by route: the molecule, oral study amounts, or injectable preparations.